Chinese venture capital firm Qiming Venture Partners took the lead in the $37-million first close of Shanghai-based biopharmaceutical firm Alpha Biopharma (AlphaBio)’s Series A financing.
The funding round also saw the participation of TF Fund and the LYZZ Healthcare Venture Fund, according to a AlphaBio press release. The firm is looking at raising $65 million for the entire Series A financing round.
